Evelo Biosciences WKN: A2JLXN ISIN: US2997341035
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
Anzeige
![Smartbroker]()
Alles ab 0 Euro pro Order. Dauerhaft.
Schorsch11,
31.01.2020 21:12
0.81% of Shares Held by All Insider
86.45% of Shares Held by Institutions
87.16% of Float Held by Institutions
68 Number of Institutions Holding Shares
https://finance.yahoo.com/quote/EVLO/holders?p=EVLO
Schorsch11,
31.01.2020 21:02
Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4304771?source=ansh $EVLO
Schorsch11,
31.01.2020 20:58
2020 clinical priorities and expected milestones
EDP1815 Psoriasis
- Data from Phase 1b trial with new formulation 2Q 2020
- Initiate Phase 2 trial 2Q 2020
- Interim data from Phase 2 trial 4Q 2020
EDP1815 Atopic Dermatitis
Data from Phase 1b trial with new formulation 2Q 2020
EDP1066 Atopic Dermatitis
Data from Phase 1b trial with new formulation 1Q 2020
EDP1867 Asthma
Initiate Phase 1b trial 2H 2020
EDP1503 Oncology
Additional clinical data from Phase 1/2 trial in MSS-CRC, TNBC, relapsed responders incl NCLC 1H 2020
Schorsch11,
31.01.2020 20:49
57 gelistete Patente
https://patentscope.wipo.int/search/en/result.jsf?_vid=P10-K62KY0-45838
4 klinische Studien
https://clinicaltrials.gov/ct2/results?cond=&term=evelo+biosciences+&cntry=&state=&city=&dist=
Schorsch11,
31.01.2020 20:45
PRICE TO BOOK 2.48
MARKET CAP 199,894,715
SHARES 32,085,829
AV. DAILY VOLUME 88,435
Cash: 97.1mio$
Burn: 6.5mio$
reicht bis Ende 2020
|
|
Kommentare | ||
|---|---|---|---|
| 1 | EVELO BIOSCIENC. DL-,001 Hauptdiskussion |
Kursdetails
| Geld (bid) | 1,83 (1.300) |
|---|---|
| Brief (ask/offer) | 1,84 (34.400) |
| Spread | 0,54 |
| Geh. Stück | 203 Tsd. |
| Eröffnung | 1,65 |
| Vortag | 1,59 |
| Tageshoch | 1,86 |
| Tagestief | 1,65 |
| 52W Hoch | 17,13 |
| 52W Tief | 1,59 |
Tagesvolumen
| in USD gehandelt | 203 Tsd. Stk |
|---|---|
| Gesamt | 203 Tsd. Stk |
Anzeige
![Smartbroker]()
Der Broker von Deutschlands größter Finanzcommunity
Börsennotierung
| Marktkapitalisierung in EUR |
|---|
| 8,3 Mrd. |
| Anzahl der Aktien |
| 53,7 Mio. |
Grundlegende Daten zur EVELO BIOSCIENC. DL-,001 Aktie
| Finanzdaten | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e |
|---|---|---|---|---|---|---|---|
| KUV | - | - | - | - | - | - | - |
| Ergebnis je Aktie (bereinigt) | - | - | - | - | - | - | - |
| Cashflow | - | - | - | - | - | - | - |
| Eigenkapitalquote | - | - | - | - | - | - | - |
| Verschuldungsgrad | - | - | - | - | - | - | - |
| Eigenkapitalrendite | - | - | - | - | - | - | - |
| Gesamtkapitalrendite | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - |
| Fundamentaldaten | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e |
| KCV | - | - | - | - | - | - | - |
| Dividendenrendite | - | - | - | - | - | - | - |
| Kurs-Gewinn-Verhältnis (KGV) | - | - | - | - | - | - | - |
| Dividende je Aktie | - | - | - | - | - | - | - |
| Bilanzdaten | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e |
| Netto-Provisionsüberschuss | - | - | - | - | - | - | - |
| Umsatzerlöse | - | - | - | - | - | - | - |
| Ergebnis vor Steuern | - | - | - | - | - | - | - |
| Steuern | - | - | - | - | - | - | - |
| Ausschüttungssumme | - | - | - | - | - | - | - |
| Nettoverzinsung | - | - | - | - | - | - | - |
| Zinsertrag | - | - | - | - | - | - | - |
| Gesamtertrag | - | - | - | - | - | - | - |